Resveratrol is a type of polyphenolic antioxidant primarily found in grapes, berries, peanuts, and other fruits. It is an antiviral substance secreted by plants to combat external stressors such as trauma, bacteria, infections, and ultraviolet radiation, acting as a guardian for plants. Notably, Resveratrol gained worldwide fame due to the "French Paradox" discussion in the 1990s, which suggested that the French, despite consuming high-fat diets, had lower rates of cardiovascular disease because of the Resveratrol in the red wine they frequently drank.
Since then, Resveratrol has been continuously studied for its potential health benefits, including anti-aging, anti-diabetic, anti-cancer, and anti-dementia effects. However, most of these findings are based on animal studies, with insufficient human clinical validation. Resveratrol generally exists in two isomeric forms, cis and trans, with the trans form being more stable (Trans-resveratrol is the most common in nature). Many of its benefits, such as regulating inflammatory pathways and anti-proliferation, are observed only in the trans form, making it the mainstream choice for health supplements and the primary focus of research.
Diabetes is one of the most common chronic diseases but also one of the most preventable. However, its preventable nature often leads to complacency. The main issue with diabetes is atherosclerosis, which significantly increases the risk of heart attacks and strokes. If it affects the kidney’s capillaries, it can further lead to kidney failure. Thus, blood sugar control is a matter of life and death (in the U.S. alone, 70,000 people die annually from diabetes complications).
A small-scale study found that overweight individuals who took Resveratrol (150 mg daily for 30 days, using DSM’s patented resVida) experienced improved blood glucose levels (a 4.2% decrease) and insulin concentrations (a 13.7% decrease).
A recent meta-analysis (including 11 studies with 388 participants) also found that Resveratrol improved fasting blood glucose, insulin, and glycated hemoglobin (HbA1c) in diabetic patients. However, these improvements were not observed in non-diabetic individuals.
According to the World Health Organization, an estimated 2.3 billion people worldwide are overweight (ages 15+), with 700 million meeting the criteria for obesity.
Obesity increases the risk of type 2 diabetes, cardiovascular disease, hypertension, hyperlipidemia, and various cancers.
A large-scale observational study (tracking 500,000 men and women over 10 years) found that being overweight increases mortality rates by 20% to 40%, making it 2 to 3 times higher than those with normal weight.
A systematic review (including 7 studies with 208 participants) indicated that Resveratrol supplementation did not significantly affect weight management, fat reduction, or abdominal obesity in overweight individuals. However, one positive finding was that Resveratrol reduced the inflammatory marker IL-6.
Researchers noted that weight loss is a gradual process, and due to limitations such as small sample sizes, heterogeneity, and short study durations (mostly less than 90 days), further confirmation is needed.
Cardiovascular disease, commonly referred to as heart disease, is primarily caused by insufficient blood flow leading to oxygen deprivation in heart tissues. The danger lies in its often asymptomatic nature, with a 30% fatality rate upon sudden onset.
Coronary artery disease (including angina and myocardial infarction) is the most common type, typically occurring in men aged 40–60 and women over 50. It is the leading cause of sudden death (accounting for about 70% of heart disease-related deaths).
A 6-month study involving 34 patients with metabolic syndrome found that Resveratrol (100 mg daily) improved vascular health markers, such as endothelial function, though other blood parameters remained unchanged.
Another double-blind, controlled study (75 participants, one-year duration) found that Resveratrol significantly reduced inflammatory markers, including C-reactive protein (CRP) and tumor necrosis factor (TNF-α), while also lowering the thrombotic factor plasminogen activator inhibitor-1 (PAI-1), suggesting its potential as a key component in preventing cardiovascular disease.
The brain typically follows one or more aging pathways. With normal aging, cognitive decline usually begins after age 80 if physical and mental health are maintained. Another pathway involves dementia, characterized by brain cell damage leading to memory and cognitive impairment, eventually affecting daily functioning.
Alzheimer’s disease, the most common form of dementia, is marked by extracellular beta-amyloid plaques and tau protein-induced neurofibrillary tangles, causing neuronal dysfunction and death.
Animal studies show that Resveratrol extends lifespan and reduces beta-amyloid and tau aggregation, protecting neurons and slowing cognitive decline. However, human studies are still needed.
A small human study (overweight individuals aged 50–75) found that Resveratrol (200 mg daily for 26 weeks) improved glucose metabolism, body fat, memory recall (remembering more words heard 30 minutes prior), and hippocampal connectivity (critical for long-term memory formation).
Choroidal neovascularization (CNV) is a complex complication of wet AMD, leading to macular edema, retinal pigment epithelium degeneration, and even retinal detachment, potentially causing blindness if untreated. VEGF inhibitors are the primary treatment to slow abnormal blood vessel growth and vision loss.
A preliminary study found that Resveratrol inhibits VEGF, reducing CNV (triggered by TGF-β or hypoxia), potentially slowing AMD progression.
Another small study found that Resveratrol (measured one hour after intake) increased choroidal thickness (improving blood flow and reducing AMD risk). However, no direct evidence yet confirms Resveratrol’s role in AMD treatment, requiring further research.
Caloric restriction (20–40% reduction while maintaining nutrition) is the most effective scientifically supported method for extending lifespan. Animal studies show it can increase lifespan by up to 60%, though long-term human studies are pending.
A 6-month human study found caloric restriction reduced insulin levels, body temperature, and DNA damage, lowering risks of metabolic syndrome, cardiovascular disease, and cancer. Resveratrol mimics some effects of caloric restriction, activating the SIRT1 longevity gene.
An animal study (high-calorie diet groups) found Resveratrol increased survival rates by 31%, improving insulin sensitivity, blood sugar control, mitochondrial function, and activity. Human lifespan effects remain unconfirmed.
Ulcerative colitis, a type of inflammatory bowel disease, causes symptoms like bloody diarrhea and abdominal cramps due to chronic immune-mediated inflammation (primarily affecting the intestinal mucosa). Patients also face higher colon cancer risks. Oxidative stress plays a key role in disease progression, and Resveratrol’s antioxidant properties make it a research focus.
A double-blind study (56 mild-to-moderate ulcerative colitis patients, 6 weeks) found Resveratrol (500 mg daily) reduced malondialdehyde (MDA, a marker of oxidative stress) while increasing total antioxidant capacity and superoxide dismutase (SOD). The Resveratrol group also showed improved disease activity and quality of life compared to placebo.
Arshine Lifescience Inc.,
Your Trusted Ingredient Partner.
Add.: Ontario, California, USA
Email: info@arshineusa.com
WhatsApp: +1 6576561513
EN